ヴェリシガートは,NO/cGMP/PKG経路を通じて,CKDに関連する血管カルシ化を改善する
Chengsi Li1, Jing Li1, Chengyingjie Yang1
1Department of Cardiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, No. 1665, Kongjiang Road, Shanghai 200000, China.
International immunopharmacology
|February 22, 2026
まとめ
溶解性ガニリルサイクラース敏感剤であるヴェリシグアートは,NO/cGMP/PKG経路を活性化することで,慢性腎臓病 (CKD) の血管カルシフィケーションを効果的に治療します. この発見は,心血管疾患のリスクが高いCKD患者のための新しい治療法を提供します.
科学分野:
- ネフロロジーは腎臓科
- 心血管科学の研究について
- 薬理学 薬理学とは
背景:
- 慢性腎臓病 (CKD) は,進行的な腎臓機能喪失につながる.
- 血管カルシフィケーションは,CKDの一般的な合併症であり,心血管疾患の予測因子です.
- 溶性ガニリルサイクラゼ (sGC) 敏感剤は,潜在的な治療戦略を代表しています.
研究 の 目的:
- 慢性腎臓病に関連した血管カルシフィケーションを弱めるための vericiguat (VER) のメカニズムを調査する.
- VERがカルシウムとリンの代謝によるsGC活動の低下を緩和するかどうかを検証する.
- VERの治療効果におけるNO/cGMP/PKG経路の役割を調査する.
主な方法:
- CKDに関連した血管カルシフィケーションのインビトロおよびインビボ実験モデル.
- カルシウム濃度,骨発作マーカー,eNOS,PKG発現の評価.
- 酸化窒素 (NO) と循環グアノシンモノフォスファート (cGMP) 濃度の測定.
- L-NAMEを使用してVER効果を相反させる抑制研究.
主要な成果:
- カルシウム濃度の上昇とオステオゲンマーカーのアップレギュレーションは,CKDのラット大動脈とVSMCで観察されました.
- ヴェリシガートは,NO/cGMP/PKG経路を活性化することで,カルシフィケーションを大幅に改善しました.
- L-NAMEは, vericiguatの有益な効果を逆転させ,経路の関与を確認しました.
結論:
- ヴェリシグアートは,CKDモデルにおける血管カルシフィケーションを効果的に弱める.
- vericiguatの治療効果は,NO/cGMP/PKG経路を通して媒介されます.
- ヴェリシガートは,CKD患者における血管合併症の管理に有望であることが示されています.
関連する概念動画
Antihypertensive Drugs: Vasodilators
2.3K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.3K
Antihypertensive Drugs: Action of Calcium Channel Blockers
1.9K
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
1.9K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.6K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.6K
Nitric Oxide Signaling Pathway
6.4K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
6.4K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
649
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
649
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
591
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
591


